| Document and Entity Information - shares | 6 Months Ended | |
| Jan. 31, 2016 | Mar. 14, 2016 | |
| Document And Entity Information | ||
| Entity Registrant Name | Odyssey Group International, Inc. | |
| Entity Central Index Key | 1,626,644 | |
| Document Type | 10-Q | |
| Document Period End Date | Jan. 31, 2016 | |
| Amendment Flag | false | |
| Current Fiscal Year End Date | --07-31 | |
| Is Entity a Well-known Seasoned Issuer? | No | |
| Is Entity a Voluntary Filer? | No | |
| Is Entity's Reporting Status Current? | Yes | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Common Stock, Shares Outstanding | 114,750,000 | |
| Document Fiscal Period Focus | Q2 | |
| Document Fiscal Year Focus | 2,016 |
| Balance Sheets (Unaudited) - USD ($) | Jan. 31, 2016 | Jul. 31, 2015 |
| Current Assets: | ||
| Cash and cash equivalents | $ 1,554 | $ 5,350 |
| Total Assets | 1,554 | 5,350 |
| Current liabilities: | ||
| Accounts payable | 19,646 | 65,735 |
| Accrued wages | 86,000 | 80,000 |
| Note payable, including accrued interest | 95,307 | 17,916 |
| Total liabilities | 200,953 | 163,651 |
| Stockholders' equity (deficiency) | ||
| Preferred stock, $.001 par value; 100,000 shares authorized, no shares issued or outstanding | 0 | 0 |
| Common stock, $.001 par value; 500,000,000 shares authorized with 114,750,000 issued and outstanding | 114,750 | 114,750 |
| Additional paid-in capital | 32,750 | 32,750 |
| Deficit | (346,899) | (305,801) |
| Total stockholders' deficit | (199,399) | (158,301) |
| Total Liabilities and stockholders' equity | $ 1,554 | $ 5,350 |
| Balance Sheets (Parenthetical) - $ / shares | Jan. 31, 2016 | Jul. 31, 2015 |
| Statement of Financial Position [Abstract] | ||
| Preferred Stock, Par Value | $ .001 | $ 0.001 |
| Preferred Stock, Shares Authorized | 100,000 | 100,000 |
| Preferred Stock, Shares Issued | 0 | 0 |
| Preferred Stock, Shares Outstanding | 0 | 0 |
| Common Stock, Par Value | $ .001 | $ 0.001 |
| Common Stock, Shares Authorized | 500,000,000 | 500,000,000 |
| Common Stock, Shares Issued | 114,750,000 | 114,750,000 |
| Common Stock, Shares Outstanding | 114,750,000 | 114,750,000 |
| Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
| Jan. 31, 2016 | Jan. 31, 2015 | Jan. 31, 2016 | Jan. 31, 2015 | |
| Income Statement [Abstract] | ||||
| Revenues | $ 0 | $ 100,917 | $ 0 | $ 239,220 |
| Cost of goods sold | 0 | 88,601 | 0 | 212,690 |
| Gross profit | 0 | 12,316 | 0 | 26,530 |
| General and administrative expenses | 14,736 | 61,795 | 39,419 | 116,094 |
| Loss from operations | (14,736) | (49,479) | (39,419) | (89,564) |
| Interest expense | (1,368) | (1,186) | (1,679) | (4,580) |
| Net loss | $ (16,104) | $ (50,665) | $ (41,098) | $ (94,144) |
| Basic net loss per share: | $ 0 | $ 0 | $ 0 | $ 0 |
| Weighted average number of shares | 114,750,000 | 114,750,000 | 114,750,000 | 114,750,000 |
| Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
| Jan. 31, 2016 | Jan. 31, 2015 | |
| Operating activities | ||
| Net loss | $ (41,098) | $ (94,144) |
| Adjustments to reconcile to net cash provided by (used in) operating activities: | ||
| Increase in accounts receivable | 0 | (47,151) |
| Decrease in deposit | 0 | 210,000 |
| Increase in accounts payable | 2,623 | 66,659 |
| Increase in accrued salaries | 6,000 | 42,000 |
| Increase in accrued interest | 1,679 | 4,580 |
| Net cash provided by (used in) operating activities | (30,796) | 181,944 |
| Financing activities | ||
| Payments on note payable | 0 | (192,069) |
| Proceeds from note payable | 27,000 | 0 |
| Net cash provided by (used in) financing activities | 27,000 | (192,069) |
| Net change in cash and cash equivalents | (3,796) | (10,125) |
| Cash and cash equivalents, beginning of period | 5,350 | 45,980 |
| Cash and cash equivalents, end of period | $ 1,554 | $ 35,855 |
| 1. Nature of Operations | 6 Months Ended |
| Jan. 31, 2016 | |
| Accounting Policies [Abstract] | |
| Nature of Operations | 1. Nature of Operations The Company is a trans-disciplinary health and wellness product development Company involved in the discovery, development and commercialization of a broad range of health and wellness products to improve human health. The Company has developed, and subsequent to July 31, 2014, begun marketing a product to provide athletic enhancement products to improve the human bodys function during athletic stress (Note 6). |
| 2. Summary of Significant Accounting Policies | 6 Months Ended |
| Jan. 31, 2016 | |
| Accounting Policies [Abstract] | |
| Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) generally requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Basis of accounting The Company has not elected to adopt the option available under GAAP to measure any of its eligible financial instruments or other items. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP. Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. No fully diluted loss per share is presented, because it would be anti-dilutive. Revenue recognition The Company recognizes revenue generally when products are shipped to its customers. Sales terms do not include significant rights of return. |
| 3. Notes Payable | 6 Months Ended |
| Jan. 31, 2016 | |
| Debt Disclosure [Abstract] | |
| Notes Payable | 3. Notes Payable As of January 31, 2016, the Company has entered into multiple convertible promissory notes, which fully mature in September 2016, bear interest at 12.0% annually, and the remaining unpaid balance is convertible upon maturity at the holders option into shares of common stock at a conversion price fixed at $0.25 per share. As of January 31, 2016, these notes have a balance of $20,800 and may be converted into 83,200 shares of common stock upon maturity. Because the conversion feature does not meet the criteria for characterization as a beneficial conversion feature, no portion of the proceeds from the issuance of the note was accounted for as attributable to the conversion feature. As of January 31, 2016, the Company has carried a note payable that is subject to periodic payments that come due based on sales. The note fully matures in January 2017, bears interest at 12.5% annually, and the remaining unpaid balance is convertible upon maturity at the holders option into shares of common stock at a conversion price fixed at $0.01 per share. As of January 31, 2016, the note has a balance of $74,507 and may be converted into 7,450,700 shares of common stock upon maturity. Because the conversion feature does not meet the criteria for characterization as a beneficial conversion feature, no portion of the proceeds from the issuance of the note was accounted for as attributable to the conversion feature. |
| 4. Fair Value Measurements | 6 Months Ended |
| Jan. 31, 2016 | |
| Fair Value Disclosures [Abstract] | |
| Fair Value Measurements | 4. Fair Value Measurements The carrying values of cash and cash equivalents and notes payable approximate their estimated fair values because of the short-term nature of these instruments. |
| 5. Income Taxes | 6 Months Ended |
| Jan. 31, 2016 | |
| Income Tax Disclosure [Abstract] | |
| Income Taxes | 5. Income Taxes As of January 31, 2016 and 2015, the Company has net deferred tax assets of $130,162 and $84,197 consisting of net operating loss carryforwards that expire in 2036 and 2035 net of an effective offsetting valuation allowance of 100%. The Company has established the valuation allowance because due to substantial uncertainty as to the Companys ability to continue as a going concern (Note 6), it is more likely than not at this time that the deferred tax assets will not be realized within the carryforward period. |
| 6. Going Concern | 6 Months Ended |
| Jan. 31, 2016 | |
| Risks and Uncertainties [Abstract] | |
| Going Concern | 6. Going Concern Although the Company realized no revenues for the six months ended January 31, 2016, it developed and commercialized a formula in fiscal year 2015, Fit, which improves the human bodys function during athletic stress. In August 2014, the Company entered into a distribution agreement for its product, Fit, and began to record its first sales of this product in the year ended July 31, 2015, but it continued to incur losses through that January 31, 2016. As a result, the Company has an operating deficit of $346,899 as of January 31, 2016. In August 2015, the Company terminated its distribution agreement. On August 4, 2015, the Board of Directors authorized the Company to register for international business operations, including selection of an international manufacturer of the Companys product. The Company has approached the new manufacturer, but has not yet entered into a final business agreement. The Company intends to continue domestic operations and approach other domestic distributors to sell its product. The Company is also reviewing its business model to distribute product on its own. Subsequent to January 31, 2016, the Company also entered into a distribution agreement to assist in the distribution of the product, CardioMap (Note 7), a product developed by a third party. These factors indicate substantial uncertainty about the Companys ability to continue as a going concern. Managements plans to overcome this uncertainty may include a new marketing strategy, which may base itself on informal networking and marketing efforts through cost effective social media outlets, rather than using more traditional marketing strategies in the industry ( i.e. |
| 7. Subsequent Event | 6 Months Ended |
| Jan. 31, 2016 | |
| Subsequent Events [Abstract] | |
| Subsequent Event | 7. Subsequent Event On February 4, 2016, the Company entered into a distribution agreement to sell and distribute a new technology, CardioMap, which is an advanced technology for early non-invasive testing of heart disease. The distribution agreement has a 5 year term and grants the Company the right to import, license, promote, and distribute the product. |
| 2. Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
| Jan. 31, 2016 | |
| Accounting Policies [Abstract] | |
| Use of estimates | Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) generally requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. |
| Basis of accounting | Basis of accounting The Company has not elected to adopt the option available under GAAP to measure any of its eligible financial instruments or other items. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP. |
| Net loss per share | Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. No fully diluted loss per share is presented, because it would be anti-dilutive. |
| Revenue recognition | Revenue recognition The Company recognizes revenue generally when products are shipped to its customers. Sales terms do not include significant rights of return. |
| 3. Notes Payable (Details Narrative) | 6 Months Ended |
| Jan. 31, 2016USD ($)$ / sharesshares | |
| Multiple Notes Payable [Member] | |
| Maturity date | Sep. 30, 2016 |
| Interest rate | 12.00% |
| Conversion price per share | $ / shares | $ .25 |
| Balance, end of period | $ | $ 20,200 |
| If converted, common shares to be issued | shares | 83,200 |
| Convertible Note Payable [Member] | |
| Maturity date | Jan. 31, 2017 |
| Interest rate | 12.50% |
| Conversion price per share | $ / shares | $ .01 |
| Balance, end of period | $ | $ 74,507 |
| If converted, common shares to be issued | shares | 7,450,700 |
| 5. Income Taxes (Details Narrative) - USD ($) | 6 Months Ended | |
| Jan. 31, 2016 | Jan. 31, 2015 | |
| Income Tax Disclosure [Abstract] | ||
| Net deferred tax assets | $ 130,162 | $ 84,197 |
| Operating loss carryforward | $ 130,162 | $ 84,197 |
| Net operating loss carryforwards expiration date | Dec. 31, 2036 | Dec. 31, 2035 |
| Net effective offsetting valuation allowance | $ 130,162 | $ 84,197 |
| 6. Going Concern (Details Narrative) - USD ($) | Jan. 31, 2016 | Jul. 31, 2015 |
| Risks and Uncertainties [Abstract] | ||
| Operating deficit | $ (346,899) | $ (305,801) |
